Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Von Eschenbach still in limbo

Executive Summary

Senate Finance Committee Chair Chuck Grassley (R-Iowa) places a hold on the nomination of Andrew von Eschenbach to be permanent FDA commissioner Nov. 16. The senator objects to von Eschenbach's "failure to comply with the committee's subpoenas over the past six months." In May, Grassley requested a briefing by senior FDA staff, a meeting with a line investigator and access to study data related to Sanofi-Aventis' Ketek (telithromycin) after allegations of data integrity problems in the antibiotic's NDA. Grassley is the third Senator to place a hold on the nomination, following Sens. David Vitter (R-La.) and Jim DeMint (R-S.C.). Senate Health Committee Chair Mike Enzi (R-Wyo.) has vowed to work to lift the holds to allow for confirmation before Congress adjourns (1"The Pink Sheet" Sept. 25, 2006, p. 4)...

You may also be interested in...

Von Eschenbach Receiving HELP With GOP Nomination Hurdles

Senate Health, Education, Labor & Pensions committee members are working to end Republican holds on the nomination of FDA Acting Commissioner Andrew von Eschenbach to the permanent post

Industry Self-Regulation Group’s Knowledge Of Drug Types Questioned By US Homeopathic Firm

Avadim Health argues National Advertising Division expects substantiation for its homeopathic topical claims at the same level FDA requires for NDAs. NAD also said although FTC’s competent, reliable scientific evidence standard is “flexible” to some degree, pain claims are held to a more rigid standard.

Novartis Takes Huntington's Path With SMA Therapy Branaplam

With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts